Prediabetes / Type 2 DiabetesNCT07195994
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
A study testing AMPK Charge+® and AMPK Charge+® with semaglutide in people with Prediabetes / Type 2 Diabetes, run by QuickSilver Scientific at 1 site in Canada.
Trial summary
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Prediabetes / Type 2 Diabetes
- What is being tested?
- AMPK Charge+® and AMPK Charge+® with semaglutide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteCanada
- Study dates
- 5 Feb 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Males \& females between 18 years of age or older
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
Show all 17Show fewer
- Intrauterine devices
- Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Abstinence and agrees to use contraception if becomes sexually active during this study
- Individuals eligible for, but not currently taking, semaglutide therapy as per standard-of-care including adults with:
- Prediabetes (HbA1c 6.0-6.5%) who are treatment naïve
- Type 2 Diabetes (HbA1c 6.5-7.5%) who are treatment naïve and metformin is inappropriate due to contraindication or intolerance
- Self-reported stable body weight defined as not having gained or lost more than 5 kg of body weight in the three months prior to baseline
- Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, use of nicotine, tobacco and cannabinoid products) as much as possible throughout the study
- Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
- Provided voluntary, written, informed consent to participate in the study
Who cannot join
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, intolerance, or dietary restriction preventing use of study products
- Personal or family history of MTC or in patients with MEN 2
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
- Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
Show all 23Show fewer
- Type I diabetes or diabetic ketoacidosis
- Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
- History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
- Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- Individuals with an autoimmune disease or are immune compromised
- Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
- Self-reported confirmation of blood/bleeding disorders as assessed by the QI
- Alcohol intake average of >2 standard drinks per day as assessed by the QI
- Alcohol or drug abuse within the last 12 months
- Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the study products (See Section 7.3)
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
- Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
KGK Science Inc.
London, Ontario, N6B3L1
Marc Moulin, PhD, +12267819094;ext=300, mmoulin@kgkscience.com
bhallam@kgkscience.com
About this study
Official title: A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. The main question it aims to answer is:
What is the difference in change in fasting blood glucose and insulin, and hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide?
Participants will consume AMPK Charge+® with or without semaglutide injections and will be evaluated for glycemic response parameters.
- Conditions
- Prediabetes / Type 2 Diabetes
- Being tested
- AMPK Charge+®, AMPK Charge+® with semaglutide
- Keywords
- Prediabetes, AMPK Charge+®, Semaglutide, GLP-1 agonist
- Medical subject headings
- Prediabetic State, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AMPK Charge+®Dietary supplement
Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1.
AMPK Charge+® with semaglutideDietary supplement
Participants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period.
| Study group | Role | What they receive |
|---|---|---|
| AMPK Charge+® | Experimental | AMPK Charge+® is a dietary supplement comprised of highly purified phospholipids, diindolylmethane, quercetin dihydrate, milk thistle seed extract, resveratrol, and berberine delivered using liposomal and nanoemulsion technology. Receives: Dietary Supplement: AMPK Charge+® |
| AMPK Charge+® with semaglutide | Active comparator | Subcutaneous semaglutide (Ozempic®), a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with T2D to improve glycemic control with the safety and efficacy extensively investigated leading to approvals by the United States (U.S.) Food and Drug Administration and Health Canada Receives: Dietary Supplement: AMPK Charge+® with semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in fasting blood glucose from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
Measured: Day 0 to 84
The difference in change in fasting insulin between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in fasting insulin from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
Measured: Day 0 to 84
The difference in change in hemoglobin A1c (HbA1c) between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
Measured: Day 0 to 84
Secondary outcomes (22)
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting blood glucose
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting blood glucose
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in HbA1c
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting HbA1c
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting insulin
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting insulin
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in Total Cholesterol (TC),
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Total Cholesterol (TC),
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in Low-Density Lipoprotein (LDL) cholesterol
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in High-Density Lipoprotein (HDL) cholesterol
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in High-Density Lipoprotein (HDL) cholesterol
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in , High-Density Lipoprotein (HDL) cholesterol
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in , High-Density Lipoprotein (HDL) cholesterol
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in ,Triglycerides (TG),
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Apolipoprotein B100 (ApoB100)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Apolipoprotein B100 (ApoB100)
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
Measured: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
Measured: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
The difference in change from baseline at Day 42 between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
Measured: Day 0 to 42
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Postprandial glucose and insulin as assessed by an oral glucose tolerance test (OGTT)
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Postprandial glucose and insulin as assessed by an oral glucose tolerance test (OGTT)
Measured: Day 0 to 84
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start5 Feb 2026
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prediabetes / Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- QuickSilver Scientific
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Responsible party
- Sponsor
- Investigators
- David Crowley, MD, Principal investigator, KGK Science Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07195994
- Sponsor's protocol ID
- 24QSCFA02
- Status last verified
- Mar 2026
- First submitted
- 18 Sep 2025
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07195994
- Acronym / sponsor ID
- 24QSCFA02
- Conditions
- Prediabetes / Type 2 Diabetes
- Keywords
- Prediabetes, AMPK Charge+®, Semaglutide, GLP-1 agonist
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- QuickSilver ScientificIndustry (pharma, biotech, devices)
- Collaborators
- KGK Science Inc.
- Study start
- 5 Feb 2026 (actual)
- Primary completion
- Sep 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. The main question it aims to answer is:
What is the difference in change in fasting blood glucose and insulin, and hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide?
Participants will consume AMPK Charge+® with or without semaglutide injections and will be evaluated for glycemic response parameters.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AMPK Charge+® | Experimental | Dietary Supplement: AMPK Charge+®AMPK Charge+® is a dietary supplement comprised of highly purified phospholipids, diindolylmethane, quercetin dihydrate, milk thistle seed extract, resveratrol, and berberine delivered using liposomal and nanoemulsion technology. |
| AMPK Charge+® with semaglutide | Active comparator | Dietary Supplement: AMPK Charge+® with semaglutideSubcutaneous semaglutide (Ozempic®), a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with T2D to improve glycemic control with the safety and efficacy extensively investigated leading to approvals by the United States (U.S.) Food and Drug Administration and Health Canada |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- Males \& females between 18 years of age or older
- Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- Or,
- Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Individuals eligible for, but not currently taking, semaglutide therapy as per standard-of-care including adults with:
Key exclusion criteria (23 listed)
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, intolerance, or dietary restriction preventing use of study products
- Personal or family history of MTC or in patients with MEN 2
- Unstable metabolic disease or chronic diseases as assessed by the QI
- Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AMPK Charge+®Participants will be instructed to consume 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. | Dietary supplement | AMPK Charge+® |
| AMPK Charge+® with semaglutideParticipants will be instructed to use the provided measuring tool to take 1 teaspoon (5 mL) on an empty stomach before breakfast and 1 teaspoon on an empty stomach in the afternoon and to hold the product in the mouth for approximately 30-90 seconds before swallowing starting on Day 1. Participants will be instructed to administer subcutaneous semaglutide once per week beginning with a dose of 0.25 mg for four weeks at which point participants will be instructed to increase the dose to 0.5 mg per week for the remainder of the study period. | Dietary supplement | AMPK Charge+® with semaglutide |
Primary outcome
The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide
Time frame: Day 0 to 84
The difference in change in fasting blood glucose from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in fasting insulin between AMPK Charge+® and AMPK Charge+® with semaglutide
Time frame: Day 0 to 84
The difference in change in fasting insulin from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in hemoglobin A1c (HbA1c) between AMPK Charge+® and AMPK Charge+® with semaglutide
Time frame: Day 0 to 84
The difference in change in hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
22 secondary outcomes
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting blood glucose
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in HbA1c
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting insulin
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in High-Density Lipoprotein (HDL) cholesterol
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in , High-Density Lipoprotein (HDL) cholesterol
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Apolipoprotein B100 (ApoB100)
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight
Time frame: Day 0 to 42
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
Time frame: Day 0 to 84
The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)
Time frame: Day 0 to 42
The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Postprandial glucose and insulin as assessed by an oral glucose tolerance test (OGTT)
Time frame: Day 0 to 84
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
Related trials for Prediabetes / Type 2 Diabetes
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Recruiting
CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes
PreDiabetes
Active, not recruitingPhase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Cushing Syndrome
Recruiting
Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes
PreDiabetes, Diet, Healthy
Not yet recruiting
Evaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality
Diabetes Mellitus (Type 2), Prediabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Crowley, MD principal investigator
KGK Science Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AMPK Charge+® and AMPK Charge+® with semaglutide in people with Prediabetes / Type 2 Diabetes, run by QuickSilver Scientific at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marc Moulin, PhD (2267819094, mmoulin@kgkscience.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide (time frame: Day 0 to 84). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.